The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 3.40
High: 3.40
Low: 3.40
Prev. Close: 3.40
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations

Mon, 04th Dec 2023 10:23

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cornerstone FS PLC, up 26% at 14.48 pence, 12-month range 5.30p-18.50p. The cloud-based payment services provider predicts 2023 adjusted earnings before interest, tax, depreciation and amortisation "materially above current market expectations". "I am pleased to be able to report that we are continuing to experience excellent trading momentum. This reflects the actions that we have taken during the year to enhance our sales team and expand our offer, such as by broadening the range of currencies and countries where we can transact," Chief Executive Officer James Hickman said.

----------

Deltex Medical Group PLC, up 19% at 0.18 pence, 12-month range 0.14p-1.60p. The maker of blood circulation monitoring systems says testing of its TrueVue monitor "has gone to plan" in recent months. "The first in market sale of the new TrueVue monitor was completed at the end of November 2023. In addition, the company has received initial orders for new TrueVue monitors, which it expects to fulfil over the coming months," Deltex adds.

----------

AIM - LOSERS

----------

Fusion Antibodies PLC, down 25% at 4.38p, 12-month range 3.02p-70.00p. The contract research organisation, providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market, reports weaker half-year earnings. Revenue falls to GBP541,000 in the six months to September 30, from GBP1.9 million a year prior. Its pretax loss widens to GBP1.4 million from GBP1.3 million. However, Fusion Antibodies is "confident" that its growth prospects are "increasingly positive", noting that it expects full-year revenue to be "significant weighted towards" the second half of the year ending on March 31.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
30 Mar 2020 16:52

Fusion Antibodies Trading In Line With Expectations Amid Outbreak

Fusion Antibodies Trading In Line With Expectations Amid Outbreak

Read more
17 Mar 2020 15:54

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

Read more
3 Feb 2020 17:32

DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Boss Buys GBP200,000 Worth

DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Boss Buys GBP200,000 Worth

Read more
29 Jan 2020 13:35

Fusion Antibodies Expects Annual Revenue Rise Ahead Of Expectations

Fusion Antibodies Expects Annual Revenue Rise Ahead Of Expectations

Read more
29 Jan 2020 09:32

Fusion Antibodies sees 'favourable trends' continue in H2

(Sharecast News) - Pre-clinical therapeutic drug and diagnostics firm Fusion Antibodies said on Wednesday that trading in the third quarter of the financial year had continued the "favourable trends" experienced in the first half.

Read more
10 Jan 2020 12:09

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Mawson Buys Shares

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Mawson Buys Shares

Read more
3 Dec 2019 18:08

DIRECTOR DEALINGS: Fusion Antibodies Non-Exec Mawson Buys Shares

DIRECTOR DEALINGS: Fusion Antibodies Non-Exec Mawson Buys Shares

Read more
2 Dec 2019 11:27

Fusion Antibodies cuts losses after revenue leaps

(Sharecast News) - Fusion Antibodies on Monday reported a narrowed loss after revenue more than doubled following the launch of its RAMP service.

Read more
2 Dec 2019 10:49

Fusion Antibodies Revenue Takes Off But Order Visibility Cloudy

Fusion Antibodies Revenue Takes Off But Order Visibility Cloudy

Read more
22 Oct 2019 15:13

Fusion Antibodies pleased with progress in first half

(Sharecast News) - Preclinical antibody discovery company Fusion Antibodies updated the market on the six months ended 30 September on Tuesday, reporting continued revenue growth amid the commercial roll out of new services.

Read more
22 Oct 2019 14:31

Fusion Antibodies Predicts Rise In Interim Revenue And Orders

Fusion Antibodies Predicts Rise In Interim Revenue And Orders

Read more
3 Jul 2019 17:03

DIRECTOR DEALINGS: Fusion Antibodies CEO, Non-Executives Buy Shares

(Alliance News) - Fusion Antibodies PLC said Wednesday that its Chief Executive Officer and two Non-Executive Directors have bought around GBP31,794 in shares in the company in deals on Executive

Read more
2 Jul 2019 10:46

Fusion Antibodies Annual Loss Widens After Rocky First Half

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss gapped wider after a weak first half brought annual revenue down 19%, though this was followed by a much stronger second antibody a

Read more
17 Apr 2019 11:49

Fusion Antibodies Annual Revenue Declines On Weak First Half

LONDON (Alliance News) - Fusion Antibodies PLC on Wednesday reported an improved performance in the second half of its recently ended financial year after "disappointing" first company a

Read more
17 Apr 2019 10:46

Fusion Antibodies revenues soar in strong second half

(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies reported a strong second half on Wednesday, driven by a significant increase in orders.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.